intelligence360
  • About us
  • Contact Us
  • Search Icon

intelligence360

The Intelligent News Source

Wavegate Corporation Announces $26 Million Series A Funding Round Led by UCEA Capital Partners Ltd.

Wavegate Corporation Announces $26 Million Series A Funding Round Led by UCEA Capital Partners Ltd.

December 20, 2024 Craig Etkin

LAKE CHARLES, La., Dec. 10, 2024 /PRNewswire/ — Wavegate Corporation, a pioneering developer of neuromodulation technology for chronic pain management, has secured a lead investor in their $26 million Series A funding round led by UCEA Capital Partners Ltd., a London-based investment firm. This financing will accelerate the development of Wavegate’s proprietary Ellipse™ platform, featuring StimuLux™ technology, designed to provide breakthrough therapeutic solutions for chronic pain patients.

Wavegate’s Ellipse™ spinal cord stimulator uses optical reflectometry to provide closed-loop adaptive modulation, uniquely adjusting stimulation in real-time based on spinal cord movement. This technology, which received FDA Breakthrough Device designation, offers significant potential to improve the lives of chronic pain sufferers by maintaining consistent pain relief across a range of patient activities using either paresthesia-based or paresthesia-free neuromodulation. Wavegate also recently achieved successful first-in-human data, further validating the clinical promise of its Ellipse™ platform.

“Securing this funding represents a pivotal moment for Wavegate as we continue to push the boundaries in neuromodulation technology,” said Dr. Erich Wolf, CEO of Wavegate Corporation. “UCEA’s investment validates the potential of our innovations and supports our vision of advancing effective, patient-centered pain management solutions.”

The investment by UCEA Capital Partners aligns with its strategic focus on supporting transformative healthcare technologies. “Wavegate’s approach to neuromodulation reflects exactly the type of high-impact, innovation-driven opportunity we seek to champion. We are thrilled to support their journey in addressing a critical area of unmet medical need,” noted Joao Teixeira, Chairman of UCEA Capital Partners Ltd.

The Series A funding will be instrumental in expanding Wavegate’s R&D efforts, clinical trials, and preparations for regulatory approvals, marking a significant step forward for the company as it progresses toward commercialization.

For more information on Wavegate Corporation, visit wavegate.us.

Media Contact:
Marla Miller, JD, LLM
Corporate Secretary
marla@wavegate.us
+1-337-419-1360

SOURCE Wavegate Corporation

Copyright © 2024 Cision US Inc.


Venture Capital
Cision, Lake Charles, Louisiana, Venture Capital, Wavegate Corporation

Post navigation

NEXT
LambdaTest Raises $38M to Revolutionize QA with AI-Native QA Agent-as-a-Service
PREVIOUS
Silent Push Secures $10 Million Investment and Awardable Status on Tradewinds Solution Marketplace
Comments are closed.

Categories

Recent Posts

  • Securin plans new project in Albuquerque, New Mexico August 14, 2026
  • Sam Dong plans new project in Delaware, Ohio August 14, 2026
  • Rural King plans new project in Henry County, Virginia August 14, 2026
  • Ricardo plans new project in Van Buren Township, Michigan August 14, 2026

Archives

© 2026   Copyright SI360 Inc. All Rights Reserved.